Mostrar el registro sencillo del documento

dc.rights.licenseReconocimiento 4.0 Internacional
dc.contributor.advisorEspinosa Almanza, Carmelo José
dc.contributor.authorRojas Martínez, Rigoberto
dc.coverage.temporal2020-2021
dc.date.accessioned2022-03-02T13:56:38Z
dc.date.available2022-03-02T13:56:38Z
dc.date.issued2022-02-10
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/81109
dc.descriptionilustraciones, gráficas, tablas
dc.description.abstractIntroducción: La pandemia de COVID-19 causada por el SARS-CoV-2, un 10% desarrollan enfermedad moderada a severa de los cuales 70-80% terminan en VMI. Estos pacientes con frecuencia aglomeran comorbilidades asociadas, lo que empeora el pronóstico y se asocia con tiempos prolongados en ventilación mecánica, mayor riesgo de complicaciones como la NAVM. La identificación de los factores de riesgo asociados al desarrollo de la infección son claves en el proceso de estratificación de los pacientes, permite además a los clínicos plantear la posibilidad de terapias alternativas a la VMI y contribuye al desarrollo de estrategias preventivas. Objetivo: Identificar los factores asociados para el desarrollo de NAVM en pacientes con SDRA por COVID – 19 de la UCI del Hospital Universitario Nacional 2020 -2021. Metodología: Estudio retrospectivo de casos y controles anidado en una cohorte, realizado en el periodo comprendido entre 1 de mayo de 2020 y el 30 junio de 2021, en la UCI del HUN, el estudio incluyó 70 casos con confirmación para NAVM y 250 controles de ambos sexos mayores de 18 años quien se encontraba bajo soporte VMI. Resultados: Sobre el estudio de los factores asociados al desarrollo de NAVM, se encontró al análisis crudo que el sexo masculino, los días de VMI, el uso de relajación muscular, el índice Charlson y la severidad del score SOFA estuvieron asociados al desenlace. Al ajustar por los probables factores de confusión a la regresión logística los valores de las medidas de asociación solo mostraron significancia para el sexo masculino, OR ajustado 2.29 (IC 95% 1.2 -4.3), los días de VMI, OR ajustado de 1.05 (IC 95%1.02-1.08) y el uso de relajante neuromuscular, OR ajustado de 3.58 (IC 95% CI 1.35-9.4). Conclusiones: La determinación de los factores de riesgo para el desarrollo de NAVM en el escenario COVID-19 bajo VMI permite la estratificación por grupos de riesgo sobre los cuales se pueden tomar intervenciones preventivas relacionado con los riesgos relativos a la terapia. Palabras claves: neumonía asociada a la ventilación mecánica, COVID-19, síndrome de dificultad respiratoria aguda (SDRA), cuidado crítico. (Texto tomado de la fuente).
dc.description.abstractIntroduction: The COVID-19 pandemic caused by SARS-CoV-2, 10% develop moderate to severe disease, of which 70-80% end up in VMI. These patients often have associated comorbidities, which worsens the prognosis and is associated with prolonged times on mechanical ventilation, higher risk of complications such as VAP. The identification of the risk factors associated with the development of the infection are key in the process of patient stratification, it also allows clinicians to consider the possibility of alternative therapies to IMV and contributes to the development of preventive strategies. Objective: To identify the associated factors for the development of VAP in patients with ARDS due to COVID - 19 of the ICU of the National University Hospital 2020 -2021. Methodology: Retrospective study of cases and controls nested in a cohort, carried out in the period between May 1, 2020 and June 30, 2021, in the ICU of the HUN, the study included 70 cases with confirmation for VAP and 250 controls of VAP. both sexes over 18 years of age who were under IMV support. Results: Regarding the study of the factors associated with the development of VAP, the crude analysis found that male sex, days of VMI, the use of muscle relaxation, the Charlson index and the severity of the SOFA score were associated with the outcome. When adjusting for the probable confounding factors to the logistic regression, the values of the association measures only showed significance for the male sex, adjusted OR 2.29 (95% CI 1.2 - 4.3), the days of mechanical ventilation, adjusted OR of 1.05 (95% CI 1.02-1.08) and the use of neuromuscular relaxant, adjusted OR of 3.58 (95% CI 1.35-9.4). Conclusions: The determination of the risk factors for the development of VAP in the COVID-19 scenario under IMV allows the stratification by risk groups on which preventive interventions related to the risks related to therapy can be taken. Keywords: ventilator associated pneumonia (VAP), COVID 19, acute respiratory distress syndrome (ARDS), critical care.
dc.format.extentxv, 40 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610 - Medicina y salud
dc.titleFactores asociados a la presentación de neumonía asociada a la ventilación mecánica invasiva en pacientes con SDRA por COVID – 19. Hospital Universitario Nacional, Bogotá 2020 – 2021
dc.typeTrabajo de grado - Especialidad Médica
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Interna
dc.description.notesIncluye anexos
dc.coverage.cityBogotá
dc.description.degreelevelEspecialidades Médicas
dc.description.degreenameEspecialista en Medicina Interna
dc.description.researchareaMedicina Intensiva y cuidado critico
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.departmentDepartamento de Medicina Interna
dc.publisher.facultyFacultad de Medicina
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.indexedBireme
dc.relation.references1. Verity R, Okell LC , Dorigatti I y col. Estimaciones de la gravedad de la enfermedad por coronavirus 2019: un análisis basado en modelos. Lancet Infect Dis 2020; 20: 669 – 677.
dc.relation.references2. Metersky ML, Masterton RG, Lode H, Archivo TM, Jr., Babinchak T. Consideraciones sobre epidemiología, microbiología y tratamiento de la neumonía bacteriana que complica la influenza. Int J Infect Dis 2012; 16: e321 - e331.
dc.relation.references3. Rawson TM, Moore, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing COVID-19 . Clin Infect Dis. 2020. 10.1093.
dc.relation.references4. Gattinoni L, Chiumello D, Rossi S. Neumonía COVID-19: ¿ARDS o no? Crit Care. 2020; 24 (1): 154.
dc.relation.references5. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts COVID-19 disease severity: a descriptive and predictive study. Target The signal transduction. 2020; 5: 33.
dc.relation.references6. Elahe Seyed Hosseini, Narjes Riahi Kashani the novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies Virology 2020 Dec;551:1-9.
dc.relation.references7. Na Zhu, Dingyu Zhang, Wenling Wang et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 N Engl J Med. 2020 Feb 20; 382(8): 727–733.
dc.relation.references8. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. A Cell Host Microbe. 2020 Jun 10; 27(6):992-1000.e3.
dc.relation.references9. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, et al, Wang J Cell Host Microbe. 2020 Jun 10; 27(6):883-890.e2.
dc.relation.references10. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Perico L, Benigni A, Remuzzi G Nephron. 2020; 144(5):213-221.
dc.relation.references11. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Mar 29, 2020.
dc.relation.references12. Bruno François, Pierre-François Laterre et al, The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients, Crit Care. 2020; 24: 289.
dc.relation.references13. Microbial Etiology and Prognostic Factors of Ventilator-associated Pneumonia: A Multicenter Retrospective Study in Shanghai. Huang Y, Jiao Y, Zhang J, Xu J, et al, Infection Assembly of Shanghai Respiratory Society. Clin Infect Dis. 2018 Nov 13; 67(suppl_2): S146-S152
dc.relation.references14. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL Clin Infect Dis. 2016 Sep 1; 63(5):e61-e111.
dc.relation.references15. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Horan TC, Andrus M, Dudeck MA Am J Infect Control. 2008 Jun; 36(5):309-32
dc.relation.references16. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C Cochrane Database Syst Rev. 2016 Oct 25; 10():CD008367.
dc.relation.references17. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
dc.relation.references18. Whitley E, Ball J. Statistics review 3: hypothesis testing and P values. Crit Care. 2002;6(3):222-5. Erratum in: Crit Care. 2003;7(1):15.
dc.relation.references19. Ali Z, Bhaskar SB. Basic statistical tools in research and data analysis. Indian J Anaesth. 2016;60(9):662-9. Erratum in: Indian J Anaesth. 2016;60(10):790.
dc.relation.references20. Kleinbaum DG, Klein M. Logistic regression: a self-learning text. 3rd ed. New York: Springer; 2010.
dc.relation.references21. Mónica María Lopera, Revisión comentada de la legislación colombiana en ética de la investigación en salud. Biomédica 2017; 37:577-89
dc.relation.references22. Mailis Maes, Ellen Higginson, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19, UK: retrospective observational study. Crit Care. 2021; 25: 25.
dc.relation.references23. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–1062.
dc.relation.references24. Saad Nseir, Ignacio Martin-Loeches, et al. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Crit Care. 2021; 25: 177.
dc.relation.references25. Xie J, Wu W, Li S, et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med. 2020.
dc.relation.references26. RECOVERY Collaborative Group. Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020.
dc.relation.references27. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315:788–800.
dc.relation.references28. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
dc.relation.references29. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
dc.relation.references30. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020.
dc.relation.references31. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020.
dc.relation.references32. Ji Liu MM, Shenglei Zhang MM et al. Risk factors for ventilator-associated events: A prospective cohort study. AJIC, 2018 1-6.
dc.relation.references33. Bornstain, C., Azoulay, E. et al. (2004). Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia. Clin. Infect. Dis. 38, 1401–1408
dc.relation.references34. Forel, J. M., Voillet, F. et al. (2012). Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit. Care 16:R65
dc.relation.references35. Tejerina, E., Frutos-Vivar, et al. (2006). Incidence, risk factors, and outcome of ventilator-associated pneumonia. J. Crit. Care 21, 56–65.
dc.relation.references36. Sharpe, J. P., Magnotti, L. J. et al. (2014). Gender disparity in ventilator-associated pneumonia following trauma: identifying risk factors for mortality. J. Trauma Acute Care Surg. 77, 161–165.
dc.relation.references37. Forel, J. M., Voillet, F., Pulina, D. et al. (2012). Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit. Care 16: R65.
dc.relation.references38. Lewis SC, Li L, Murphy MV, Klompas M. Risk factors for ventilator-associated events: a case-control multivariable analysis. Crit Care Med 2014; 42:1839-48.
dc.relation.references39. Michael A. Smith, Maho Hibino, Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: An underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients. Ann Pharmacother. 2014 Jan; 48(1): 77–85.
dc.relation.references40. Ji Liu MM, Shenglei Zhang MM et al. Risk factors for ventilator-associated events: A prospective cohort study. AJIC, 2018 1-6.
dc.relation.references41. Moncaleano V. Boletín informativo, resultados de la vigilancia de la resistencia bacteriana Año 2018, componente pediátrico y adulto. Número 11, Bogotá 2019.
dc.relation.references42. Evans, C. R., Sharpe, J. P., Swanson, J. M., Wood, G. C., Fabian, T. C., Croce, M. A., et al. (2018). Keeping it simple: impact of a restrictive antibiotic policy for ventilator-associated pneumonia in trauma patients on incidence and sensitivities of causative pathogens. Surg. Infect. 19, 672–678.
dc.relation.references43. Diling Wu, Chenfang Wu, Siye Zhang and Yanjun Zhong. Risk Factors of Ventilator-Associated Pneumonia in Critically III Patients. Frontiers in Pharmacology 2019 Vol 10.
dc.relation.references44. Mahapatra, A., Patro, S., Sarangi, G., Das, P., Mohapatra, D., Paty, B., et al. (2018). Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital. Indian J. Pathol. Microbiol. 61, 375–379.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsRespiratory Distress Syndrome, Adult
dc.subject.decsSíndrome de Dificultad Respiratoria del Adulto
dc.subject.decsInfecciones por Coronavirus
dc.subject.decsCoronavirus Infections
dc.subject.decsNeumonía
dc.subject.decsPneumonia
dc.subject.proposalVentilator-associated pneumonia
dc.subject.proposalCOVID-19
dc.subject.proposalNeumonía asociada a la ventilación mecánica
dc.subject.proposalAcute respiratory distress syndrome (ARDS)
dc.subject.proposalCritical care
dc.subject.proposalSsíndrome de dificultad respiratoria aguda (SDRA)
dc.subject.proposalCuidado crítico
dc.title.translatedFactors associated with the presentation of Ventilator Associated Pneumonia in patients with ARDS due to COVID - 19. Hospital Universitario Nacional, Bogotá 2020 - 2021
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
dcterms.audience.professionaldevelopmentEstudiantes
dcterms.audience.professionaldevelopmentInvestigadores
dcterms.audience.professionaldevelopmentMaestros


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Reconocimiento 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito